SCHEMBL4200341

SCHEMBL4200341

Cc1ccsc1CN1CCC2(CC1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.45
ACACB O00763 5/20 0.45
CXCR4 P61073 1/20 0.45
SCD5 Q86SK9 1/20 0.44
CYP3A4 P08684 3/20 0.43
OPRM1 P35372 2/20 0.41
OPRL1 P41146 2/20 0.41
HDAC2 Q92769 1/20 0.41
ALDH1A1 P00352 2/20 0.41
RORC P51449 1/20 0.41
KDM4E B2RXH2 1/20 0.41
USP30 Q70CQ3 1/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
GPR183 P32249 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136438 0.78 CYP2D6 (0.61) CYP11B2SCD5CYP3A4ALDH1A1TSHR
SCHEMBL14139404 0.75 KDM4E (0.46) CXCR4CYP3A4OPRM1OPRL1ALDH1A1
SCHEMBL14027002 0.75 CYP2D6 (0.65) CYP3A4ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL4208866 0.74 CXCR4 (0.58) CXCR4CYP3A4ALDH1A1KDM4ETSHR
SCHEMBL6868004 0.74 CYP11B2 (0.54) CYP11B2ACACBSCD5HDAC2ALDH1A1
SCHEMBL17608988 0.73 CYP2D6 (0.64) CYP3A4ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL10201505 0.73 CYP11B2 (0.47) CYP11B2ACACBSCD5HDAC2RORC
SCHEMBL1426231 0.73 CYP2D6 (0.64) SCD5CYP3A4ALDH1A1TSHRCYP2D6
SCHEMBL15285018 0.72 CYP11B2 (0.46) CYP11B2ACACBSCD5HDAC2RORC
SCHEMBL10264330 0.72 CYP11B2 (0.46) CYP11B2ACACBSCD5HDAC2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871210-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-10-28 US disclosed
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-13 US disclosed
US-8614323-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-12-24 US disclosed
EP-2657235-A1 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-30 EP disclosed
EP-1942108-B1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-09-04 EP disclosed
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-12-27 US disclosed
US-8318931-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
US-8293896-B2 2012-10-23 US disclosed
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-05-07 US disclosed
EP-1942108-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 CYP11B2 886/4885ACACB 3506/4885CXCR4 1/4885
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CXCR1, CXCR3 CYP11B2 598/4885ACACB 3420/4885CXCR4 1/4885
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 CYP11B2 886/4885ACACB 3506/4885CXCR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.